Immune Thrombocytopenia (ITP) Clinical Trial
Official title:
Autoantibody Specificity and Response to Intravenous Immunoglobulin G (IVIG) in Immune Thrombocytopenia (ITP): a Retrospective Cohort Study
The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.
Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder, in which platelet surface GPIIb/IIIa and GPIb/IX are the two most frequently targeted autoantigens. Our previous studies in animal models of ITP demonstrated that intravenous immunoglobulin G (IVIG) could protect against anti-GPIIb/IIIa-mediated thrombocytopenia but failed to ameliorate ITP induced by most anti-GPIb/IX antibodies. The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment. ;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02868060 -
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
|
Phase 1/Phase 2 | |
| Completed |
NCT04346654 -
A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP
|
Phase 2 | |
| Not yet recruiting |
NCT06371417 -
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
|
Phase 1 | |
| Terminated |
NCT01054443 -
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
|
Phase 2 | |
| Recruiting |
NCT04915482 -
TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
|
Phase 2/Phase 3 | |
| Completed |
NCT00344149 -
Rituximab as Second Line Treatment for ITP
|
Phase 3 | |
| Completed |
NCT04669600 -
A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
|
Phase 2 | |
| Active, not recruiting |
NCT05086744 -
Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
|
Phase 2 | |
| Recruiting |
NCT03951623 -
The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
|
Phase 1 | |
| Recruiting |
NCT04968899 -
IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
|
Phase 3 | |
| Recruiting |
NCT03975361 -
Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)
|
N/A |